Patient P-02628
Therapy response
Stable
Tolerance
Stable
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
96%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 69 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 71 SC-12 recommended — Supportive Compound SC-12
- Day 72 Patient accepted — Started SC-12 in the companion
- Day 78 GI symptom burden −18% vs expected — Supportive Compound SC-12
- Day 84 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 69.
Primary contributors, last 14 days
- GI instability+6
- Inflammatory activity+2
What helped?
- Supportive Compound SC-12Day 71Result: symptom burden −18%
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 89% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↑65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 58
- WearableHRV 35 ms, trending down
- Autonomic recovery ↓65
- WearableResting HR 73 bpm
- Wearable955 steps/day
- WearableShort sleep window
- Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 63 and rising
- WearableSleep 5.6 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 39/100
- Daily logFibre intake low in recent food logs
- Drug metabolism and exposure ↑20
- BloodToxicity index 44
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 2.2 · butyrate capacity 39/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 37 ms
- Sleep
- 5.8 h
- Steps
- 680
- Resting HR
- 74 bpm
Daily log: GI score 63, nutritional resilience 41, adherence 51.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02048 | 19% | S02 | — | — | 77 |
| P-02115 | 20% | S14 | GI-04 | improved | 75 |
| P-02575 | 21% | S14 | ME-01 | improved | 73 |
| P-02335 | 19% | S04 | — | — | 70 |
| P-02550 | 20% | S01 | — | — | 70 |
| P-02192 | 19% | S05 | — | — | 69 |
| P-02659 | 23% | S09 | — | — | 69 |
| P-02293 | 19% | S15 | HY-01 | no change | 68 |
| P-02591 | 32% | S13 | — | — | 68 |
| P-02090 | 19% | S04 | — | — | 68 |
| P-02265 | 28% | S07 | GI-04 | no change | 67 |
| P-02530 | 30% | S07 | — | — | 67 |